NCT04042116
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Tyrosine-Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase (not the expansion phase)
Exclusions: Patients with active central nervous system brain metastases; Patients with prior treatment of lucitanib
https://ClinicalTrials.gov/show/NCT04042116